Home > Insider Trading > Filing (0001209191-10-051904)

Filing Details

Accession Number:: 0001209191-10-051904
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-10-27 18:06:51
Reporting Period:: 2010-10-27

Filing Date:: 2010-10-27
Accepted Time:: 2010-10-27 18:06:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198321	Farah Champsi	One Embarcadero Center Suite 3700 San Francisco CA 94132	No	No	Yes	No
1198323	Jean Deleage	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1198332	Edward Penhoet	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1211840	Edward Hurwitz	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1257444	Alta Biopharma Partners Iii Lp	One Embarcadero Center Suite 3700 CA 94111	No	No	Yes	No
1280234	Alta Biopharma Management Iii Llc	One Embarcadero Center Suite 3700 CA 94111	No	No	Yes	No
1280238	Alta Embarcadero Biopharma Partners Iii Llc	One Embarcadero Center Suite 3700 CA 94111	No	No	Yes	No
1280265	Alta Biopharma Partners Iii Gmbh & Co Beteiligungs Kg	One Embarcadero Center Suite 3700 CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-10-27	1,086,336	$0.00	1,086,336	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	379,545	$0.00	1,465,881	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	700,050	$7.60	2,165,931	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	289,236	$9.50	2,455,167	No	4	P	Direct
Common Stock	Acquisiton	2010-10-27	72,957	$0.00	72,957	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	25,490	$0.00	98,447	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	47,010	$7.60	145,457	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	19,425	$9.50	164,882	No	4	P	Direct
Common Stock	Acquisiton	2010-10-27	26,771	$0.00	26,771	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	9,353	$0.00	36,124	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	17,250	$7.60	53,374	No	4	C	Direct
Common Stock	Acquisiton	2010-10-27	7,128	$9.50	60,502	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Prefered Stock	Disposition	2010-10-27	2,806,991	$0.00	1,086,336	$0.00
Common Stock	Series A Convertible Prefered Stock	Disposition	2010-10-27	188,514	$0.00	72,957	$0.00
Common Stock	Series A Convertible Prefered Stock	Disposition	2010-10-27	69,176	$0.00	26,771	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-10-27	621,923	$0.00	379,545	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-10-27	41,768	$0.00	25,490	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-10-27	15,327	$0.00	9,353	$0.00
Common Stock	Senior Subordinated Convertible Promissory Notes	Disposition	2010-10-27	0	$0.00	700,050	$7.60
Common Stock	Senior Subordinated Convertible Promissory Notes	Disposition	2010-10-27	0	$0.00	47,010	$7.60
Common Stock	Senior Subordinated Convertible Promissory Notes	Disposition	2010-10-27	0	$0.00	17,250	$7.60

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Direct
	No	4	C	Direct
	No	4	C	Direct
	No	4	C	Direct
	No	4	C	Direct
	No	4	C	Direct
2011-12-31	No	4	C	Direct
2011-12-31	No	4	C	Direct
2011-12-31	No	4	C	Direct

Footnotes

Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series A Share converted into 0.38701117412 shares of common stock.
Alta BioPharma Management III, LLC ("ABMIII") is the general partner of ABPIII and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG"). Jean Deleage, Farah Champsi, Edward Penhoet and Edward Hurwitz are the directors of ABMIII and managers of Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII"). Alison Kiley, a director of the Issuer, is a member of ABMIII and may be deemed to share investment power over the securities of the Issuer held by ABPIII, ABPIIIKG and AEBPIII with the directors of ABMIII and managers of AEBPIII. Each of Dr. Deleage, Ms. Champsi, Dr. Penhoet and Mr. Hurwitz disclaim beneficial ownership of such securities except to the extent of his or her pecuniary interest therein.
These securities are owned directly by ABPIII.
Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series B Share converted into 0.61027657931 basis of common stock.
The outstanding principal and accrued and unpaid interest on these Convertible Notes was automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering at $7.60 per share, which is equal to 80% of the Issuer's initial public offering price per share.
These securities are owned directly by ABPIIIKG.
These securities are owned directly by AEBPIII.
The Series A Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
The Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
The Convertible Notes were issued on September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010 and October 1, 2010. Any outstanding principal amount and accrued but unpaid interest thereon was automatically convertible into shares of capital stock of the Issuer upon the consummation of specified sale transactions involving the securities of the Issuer, including an initial public offering of the Issuer's common stock meeting certain conditions.